中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 6
Jun.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(6): 1234-1236

Anticoagulant therapy and transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid related hepatic sinusoidal obstruction syndrome

DOI: 10.3969/j.issn.1001-5256.2022.06.005

  • Department of Gastroenterology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210004, China

More Information
  • Corresponding author: ZHUGE Yuzheng, yuzheng9111963@aliyun.com(ORCID: 0000-0002-3829-5831)
  • Received Date: 2022-04-18
  • Accepted Date: 2022-05-22
  • Published Date: 2022-06-20
    Abstract
  • Hepatic sinusoidal obstruction syndrome (HSOS) is a vascular liver disease characterized by varying degrees of liver injury and portal hypertension. HSOS in China is mostly associated with the intake of pyrrolizidine alkaloids. The step-up approach with anticoagulant therapy and transjugular intrahepatic portosystemic shunt (TIPS) as the core treatment methods is the therapy currently recommended for this disease. Subcutaneous injection of low-molecular-weight heparin is the first choice for anticoagulant therapy, and oral warfarin can be used in combination or sequentially to enhance anticoagulation. Patients with no response to anticoagulant therapy can switch to TIPS. The Drum Tower Severity Score (DTSS) system can be used during treatment to evaluate the severity of the disease, in order to identify high-risk patients earlier and switch to TIPS in time, thereby improving the prognosis of patients.

     

    • FullText(HTML)
  • loading
    • References(12)
  • [1]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver[J]. J Hepatol, 2016, 64(1): 179-202. DOI: 10.1016/j.jhep.2015.07.040.
    [2]
    ZHANG W, LIU L, ZHANG M, et al. Validation of the Nanjing Criteria for diagnosing pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome[J]. J Clin Transl Hepatol, 2021, 9(3): 345-352. DOI: 10.14218/JCTH.2020.00124.
    [3]
    Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing)[J]. J Clin Hepatol, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.

    中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年, 南京)[J]. 临床肝胆病杂志, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.
    [4]
    ZHUGE Y, LIU Y, XIE W, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol, 2019, 34(4): 634-642. DOI: 10.1111/jgh.14612.
    [5]
    ZHU CK, ZHANG F, ZHUGE YZ, et al. Clinical characteristics of 115 cases of gynura segetum induced hepatic sinusoidal obstruction syndrome[J]. Chin J Dig, 2017, 37(7): 448-452. DOI: 10.3760/cma.j.issn.0254-1432.2017.07.004.

    朱成凯, 张峰, 诸葛宇征, 等. 菊三七相关肝窦阻塞综合征115例的临床特征分析[J]. 中华消化杂志, 2017, 37(7): 448-452. DOI: 10.3760/cma.j.issn.0254-1432.2017.07.004.
    [6]
    MOHTY M, MALARD F, ABECASSIS M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation[J]. Bone Marrow Transplant, 2016, 51(7): 906-912. DOI: 10.1038/bmt.2016.130.
    [7]
    ZHUGE YZ, WANG Y, ZHANG F, et al. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease[J]. Liver Int, 2018, 38(10): 1867-1874. DOI: 10.1111/liv.13684.
    [8]
    PENG C, ZHANG X, ZHANG F, et al. Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective multicenter cohort study[J]. Eur J Gastroenterol Hepatol, 2020, 32(9): 1168-1178. DOI: 10.1097/MEG.0000000000001630.
    [9]
    ZHOU CZ, WANG RF, LV WF, et al. Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome[J]. World J Gastroenterol, 2020, 26(24): 3472-3483. DOI: 10.3748/wjg.v26.i24.3472.
    [10]
    XIAO J, TU J, ZHANG H, et al. Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt[J]. Hepatol Int, 2021, 15(3): 720-729. DOI: 10.1007/s12072-020-10126-x.
    [11]
    CHEN YR, ZHANG W, ZHANG M, et al. Study of PA-HSOS severity grading to predict the prognosis of patients with PA-HSOS treated by transjugular intrahepatic portosystemic shunt[J]. Chin J Hepatol, 2021, 29(1): 46-53. DOI: 10.3760/cma.j.cn501113-20201213-00651.

    陈依然, 张玮, 张明, 等. PA-HSOS严重度分级预测经颈静脉肝内门体分流术治疗PA-HSOS患者预后的研究[J]. 中华肝脏病杂志, 2021, 29(1): 46-53. DOI: 10.3760/cma.j.cn501113-20201213-00651.
    [12]
    WANG X, ZHANG W, ZHANG M, et al. Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. Hepatol Int, 2022. DOI: 10.1007/s12072-021-10293-5.[Online ahead of print]
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (839) PDF downloads(117) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return